WELCHOL Drug Patent Profile

Which patents cover Welchol, and when can generic versions of Welchol launch?

Welchol is a drug marketed by Cosette and is included in four NDAs.

The generic ingredient in WELCHOL is colesevelam hydrochloride. There are ten drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the colesevelam hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Welchol

A generic version of WELCHOL was approved as colesevelam hydrochloride by IMPAX LABS INC on May 16^th, 2018.

Summary for WELCHOL

US Patents:	0
Applicants:	1
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	28
Drug Prices:	Drug price information for WELCHOL
What excipients (inactive ingredients) are in WELCHOL?	WELCHOL excipients list
DailyMed Link:	WELCHOL at DailyMed

See drug prices for WELCHOL

See drug sales revenues for WELCHOL

Recent Clinical Trials for WELCHOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Entera Health, Inc	Phase 2
Valeant Pharmaceuticals International, Inc.	Phase 4
Bausch Health Americas, Inc.	Phase 4

See all WELCHOL clinical trials

Pharmacology for WELCHOL

Drug Class	Bile Acid Sequestrant
Mechanism of Action	Bile-acid Binding Activity

Paragraph IV (Patent) Challenges for WELCHOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WELCHOL	Powder for Oral Suspension	colesevelam hydrochloride	1.875 g/Packet and 3.75 g/Packet	022362	1	2010-04-09
WELCHOL	Tablets	colesevelam hydrochloride	625 mg	021176	1	2009-07-01

US Patents and Regulatory Information for WELCHOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	WELCHOL	colesevelam hydrochloride	BAR, CHEWABLE;ORAL	210895-001	Apr 3, 2019		DISCN	Yes	No
Cosette	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-002	Oct 2, 2009	AB	RX	Yes	Yes
Cosette	WELCHOL	colesevelam hydrochloride	CAPSULE;ORAL	021141-001	May 26, 2000		DISCN	No	No
Cosette	WELCHOL	colesevelam hydrochloride	FOR SUSPENSION;ORAL	022362-001	Oct 2, 2009		DISCN	Yes	No

Expired US Patents for WELCHOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	WELCHOL	colesevelam hydrochloride	BAR, CHEWABLE;ORAL	210895-001	Apr 3, 2019	7,229,613
Cosette	WELCHOL	colesevelam hydrochloride	TABLET;ORAL	021176-001	May 26, 2000	5,624,963
Cosette	WELCHOL	colesevelam hydrochloride	CAPSULE;ORAL	021141-001	May 26, 2000	5,624,963

International Patents for WELCHOL

See the table below for patents covering WELCHOL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	184027
Austria	205508
Australia	2012399
Australia	2556095

Supplementary Protection Certificates for WELCHOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0764174	91100	Luxembourg		91100, EXPIRES: 20190310
0764174	300159	Netherlands		300159, 20150605, EXPIRES: 20190309
0764174	CA 2004 00027	Denmark
0764174	SPC/GB04/031	United Kingdom		PRODUCT NAME: COLESEVELAM HYDROCHLORIDE; REGISTERED: UK EU/1/03/268/001-003 20040310

Last updated: July 24, 2026

Welchol (colesevelam) market dynamics and financial trajectory

Welchol’s U.S. revenue trajectory is shaped by chronic use dynamics in hyperlipidemia, ongoing generic pressure, and competitive substitution within bile acid sequestrants (BAS). In practice, the brand has remained a cash-flow product while facing sustained pricing compression. Key dynamics include: (1) shrinking “brand-only” addressable market due to generic colesevelam availability, (2) payer-driven preference for lower-cost BAS alternatives and combination products, and (3) label-constrained demand outside primary LDL-C lowering indications.

What drives Welchol (colesevelam) market demand in hyperlipidemia?

Where does Welchol sit in lipid therapy?

Welchol (colesevelam hydrochloride) is a bile acid sequestrant indicated for:

• Hypercholesterolemia (primary hyperlipidemia): as monotherapy or in combination with other lipid-lowering agents to lower LDL-C and total cholesterol.
• Type 2 diabetes mellitus (as adjunct to diet and exercise): to improve glycemic control (commonly reflected as A1c reduction), where it is positioned as an option that does not cause hypoglycemia risk like some agents.

Demand is driven primarily by the size of the statin-treated population and the subset that seeks or can tolerate BAS therapy due to tolerability, contraindications, or payer design. BAS use is typically smaller than statin and ezetimibe niches, which keeps ceiling growth limited.

What patient segments and prescriber patterns matter most?

• Patients needing additional LDL-C reduction despite statins or who cannot tolerate higher-intensity regimens.
• Patients seeking glucose-control add-ons where a non-hypoglycemic agent is preferred.
• Payers that steer toward preferred BAS options by formulary tiers and cost.

How do safety and tolerability affect adoption?

BAS class effects include GI adverse reactions (constipation is common), which can reduce persistence and switchback rates. That matters because Welchol’s economics depend on chronic refills rather than short-cycle usage.

How have generic alternatives affected Welchol pricing and unit economics?

What happens to brand economics under generic substitution?

Colesevelam has generic availability in the U.S., and that compresses brand pricing through:

• Higher brand penetration losses after generic listings.
• More aggressive pharmacy switching under copay differentials.
• Payer step edits that accelerate discontinuation.

Net result is typically lower revenue per script and reduced marketing ROI as incremental patients migrate to generics.

Where does Welchol still hold pricing power?

Welchol can retain premium dynamics only where:

• Managed care contracts keep it on formulary.
• Patients are stable on the brand and prescribers avoid switching.
• Plan designs keep a narrow spread between brand and generic co-pays.

Even in those cases, volume growth is constrained because substitution pressure is structural.

What is the financial trajectory of Welchol since generic entry?

What typically defines the curve for mature branded BAS products

For a branded lipid drug with generics in-market, the financial trajectory usually follows a pattern:

1. Pre-generic stability: supported by branded awareness, detailing, and formularies.
2. Post-generic step-down: sharp decline in brand share and pricing.
3. Steady decline or plateau: depends on contract retention, patient persistence, and competitive positioning versus other BAS.
4. Ongoing erosion: as generics expand coverage and copay thresholds lower.

Expected revenue drivers under this profile

• Persistence: patients who stay on Welchol drive the long-tail revenue.
• Formulary access: contracts and rebates determine how quickly brand penetration shrinks.
• Dose and product mix: tablet vs powder formulation mix can shift based on convenience and payer coverage.

How does Welchol compare with competing bile acid sequestrants for market share?

Which BAS competitors matter commercially?

In the U.S., the BAS competitive set typically includes:

• Cholestyramine (older BAS, lower price points, broad generic use)
• Colestipol (generic and competitive on cost)
• Other colesevelam-labeled generics that compete directly

How does colesevelam’s convenience translate into value?

Colesevelam is often favored over older BAS due to dosing flexibility and tolerability characteristics relative to some alternatives. That can support adherence. Still, the presence of multiple generic colesevelam products reduces brand share benefits unless brand-specific contracting is strong.

What does payer preference look like in practice?

Payers often steer to:

• Lowest net cost generics first.
• Preferred BAS within the class if required by step therapy.
• Combination LDL management strategies that reduce BAS add-on usage.

What Orange Book status and patent landscape affect Welchol’s long-run brand economics?

Why Orange Book matters even after brand erosion

Orange Book protection controls launch timing of true generics and, where applicable, branded lifecycle extensions. Once generics are launched, financial trajectory is more driven by:

• Contracting and formulary placement
• Brand-switch dynamics
• Inventory and supply continuity
• Litigation outcomes that might delay some entries (if any are still relevant)

How to think about “last mile” IP risk

Even when the core API is generic, remaining exclusivity and formulation-specific patents can affect:

• Competitive entry timing for dosage forms or specific product presentations
• Barriers to certain manufacturing changes
• Potential exclusivity for particular ROA combinations (if applicable)

What generic entry risks existed for Welchol, and how do settlements shape them?

Paragraph IV and settlement dynamics

For brands with legacy exclusivity, generic entry timing is frequently mediated by:

• Paragraph IV challenges
• Litigation
• Settlement “carve-out” terms that define first generic launch timing

The economic impact in this category is immediate if settlement prevents entry for a period, or gradual if brand declines regardless. For Welchol, the practical market reality is that generic availability already exists and the remaining brand economics are more contract-driven than IP-driven.

How does FDA regulatory status influence Welchol’s commercial trajectory?

What matters to ongoing access

For mature products, FDA status influences commercial trajectory through:

• Label scope consistency
• Safety signal management and label changes
• Ongoing manufacturing compliance and supply stability

Welchol’s demand depends on continued clinical positioning in hyperlipidemia and type 2 diabetes adjunct therapy rather than new indications.

What dosing forms and formulation mix matter for revenue?

Tablets vs powder mix

Welchol is marketed in multiple product forms. Revenue trajectory depends on:

• Patient preference and ease-of-use
• Insurance coverage for each presentation
• Switching behavior when co-pays differ by formulation

For established brands, formulation mix can shift to whichever presentation has the best formulary status or patient tolerability. That mix shift can stabilize revenue per patient even as overall volume declines.

What are the commercial strategy levers for a mature Welchol brand?

1) Contracting and formulary placement

The brand’s lifetime revenue is usually determined by net price, rebate structure, and whether it stays in:

• Preferred tiers
• “No prior authorization” segments
• Step therapy pathways

2) Patient persistence and prescriber inertia

Tolerability and continuity help persistence. Prescribers may continue patients already stable on Welchol rather than switching due to symptom stabilization and workflow.

3) Targeted marketing and lifecycle management

Lifecycle marketing is less about new science and more about:

• maintaining access within specific managed care networks
• supporting adherence in chronic regimens
• reinforcing adjunct roles where BAS still fits

What are the key performance indicators for investors and licensors evaluating Welchol?

Brand-style KPIs

• Prescriptions and TRx trends (by form and dosage)
• Net price and rebate evolution
• Share of volume vs generic colesevelam
• Specialty vs retail distribution shifts
• Persistence measures (time on therapy)

Payer-driven KPIs

• Formulary tier movement
• Prior authorization or step edit intensification
• Copay card usage (if applicable to current era)
• Net cost competitiveness vs preferred BAS generics

Key takeaways

• Welchol’s market dynamics are dominated by generic substitution and payer-driven net price compression rather than growth-oriented clinical expansion.
• Demand is anchored in chronic lipid and adjunct glycemic-use niches, but baseline growth is constrained by statin-led therapy dominance.
• The financial trajectory for a mature BAS brand typically shows post-generic erosion followed by contract and persistence-dependent stabilization, then continued long-tail decline.
• Competitive pressure from other BAS options and generic colesevelam products keeps brand economics sensitive to formulary positioning.

FAQs

1. Is Welchol still used for LDL lowering compared with statins and ezetimibe?
2. How do bile acid sequestrants differ in tolerability and adherence, and does that affect Welchol persistence?
3. What formulary tactics most influence continued Welchol brand volume after generic entry?
4. How does Welchol’s adjunct type 2 diabetes label translate into payer utilization versus other non-hypoglycemia agents?
5. Do dosage form differences (tablet vs powder) materially change managed care coverage and net revenue?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drug Label: Welchol (colesevelam hydrochloride). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/

DrugChatter Q&A for WELCHOL

Is Welchol used for diabetes?